Implementation Considerations for Multisite Clinical Trials with Cognitive Neuroscience Tasks
- 21 November 2007
- journal article
- review article
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin
- Vol. 34 (4) , 656-663
- https://doi.org/10.1093/schbul/sbn042
Abstract
Multisite clinical trials aimed at cognitive enhancement across various neuropsychiatric conditions have employed standard neuropsychological tests as outcome measures. While these tests have enjoyed wide clinical use and have proven reliable and predictive of functional disability, a number of implementation challenges have arisen when these tests are used in clinical trials. These issues are likely to be magnified in future studies when cognitive neuroscience (CN) procedures are explored in these trials, because in their current forms CN procedures are less standardized and more difficult to teach and monitor. For multisite trials, we anticipate that the most challenging issues will include assuring tester competence, monitoring tester performance, specific challenges with complex assessment methods, and having resources available for adequate monitoring of data quality. Suggestions for overcoming these implementation challenges are offered.Keywords
This publication has 13 references indexed in Scilit:
- Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophreniaJournal of the International Neuropsychological Society, 2008
- Baseline Neurocognitive Deficits in the CATIE Schizophrenia TrialNeuropsychopharmacology, 2006
- A comparison of cognitive structure in schizophrenia patients and healthy controls using confirmatory factor analysisSchizophrenia Research, 2006
- Treatment of Cognitive Impairment in Early Psychosis: A Comparison of Risperidone and Haloperidol in a Large Long-Term TrialAmerican Journal of Psychiatry, 2005
- Comparative Effect of Atypical and Conventional Antipsychotic Drugs on Neurocognition in First-Episode Psychosis: A Randomized, Double-Blind Trial of Olanzapine Versus Low Doses of HaloperidolAmerican Journal of Psychiatry, 2004
- The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive batteryPublished by Elsevier ,2003
- Studies of Cognitive Change in Patients With Schizophrenia Following Novel Antipsychotic TreatmentAmerican Journal of Psychiatry, 2001
- The Effects of Atypical Antipsychotic Drugs on Neurocognitive Impairment in Schizophrenia: A Review and Meta-analysisSchizophrenia Bulletin, 1999
- Cognitive impairment as a target for pharmacological treatment in schizophreniaSchizophrenia Research, 1995
- The continuous performance test, identical pairs version: II. Contrasting attentional profiles in schizophrenic and depressed patientsPsychiatry Research, 1989